Marie‐Ange Demoitié

5.2k citations

31 papers · 1.8k indexed · h-index 25

Co-authors: Opokua Ofori‐Anyinam Philippe Moris Xia Jin Douglas F. Nixon Joe Cohen Pascal Mettens Graham S. Ogg Erik Jongert
Topics: HIV Research and Treatment (14 papers)Tuberculosis Research and Epidemiology (12 papers)vaccines and immunoinformatics approaches (7 papers)
Cited by: Virology Immunology Infectious Diseases
Journals: Journal of Clinical Investigation The Journal of Immunology PLoS ONE
Partner nations: Belgium United States United Kingdom

In The Last Decade

Marie‐Ange Demoitié

31 papers receiving 1.8k citations

Peers

Countries citing papers authored by Marie‐Ange Demoitié

Since Specialization

Citations

This map shows the geographic impact of Marie‐Ange Demoitié's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marie‐Ange Demoitié with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marie‐Ange Demoitié more than expected).

Fields of papers citing papers by Marie‐Ange Demoitié

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marie‐Ange Demoitié. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marie‐Ange Demoitié. The network helps show where Marie‐Ange Demoitié may publish in the future.

Co-authorship network of co-authors of Marie‐Ange Demoitié

This figure shows the co-authorship network connecting the top 25 collaborators of Marie‐Ange Demoitié. A scholar is included among the top collaborators of Marie‐Ange Demoitié based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marie‐Ange Demoitié. Marie‐Ange Demoitié is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Non-clinical evaluation of local and systemic immunity induced by different vaccination strategies of the candidate tuberculosis vaccine M72/AS01 2023 ·Tuberculosis ·Nadia Ouaked,Marie‐Ange Demoitié,Fabrice Godfroid,(unknown),Yannick Vanloubbeeck,Stéphane Temmerman	4
2	Subsequent AS01-adjuvanted vaccinations induce similar transcriptional responses in populations with different disease statuses 2022 ·PLoS ONE ·Margherita Coccia,Wivine Burny,Marie‐Ange Demoitié,Paul Gillard,Robert A. van den Berg,Robbert van der Most	5
3	Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults 2018 ·Medicine ·Nagalingeswaran Kumarasamy,Selvamuthu Poongulali,(unknown),(unknown),(unknown),Anne Bollaerts,Marie‐Ange Demoitié,Erik Jongert,Opokua Ofori‐Anyinam,Olivier Van Der Meeren	24
4	A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults 2016 ·Medicine ·Nagalingeswaran Kumarasamy,Selvamuthu Poongulali,Anne Bollaerts,Philippe Moris,(unknown),(unknown),Marie‐Ange Demoitié,Erik Jongert,Opokua Ofori‐Anyinam	35
5	Safety and immunogenicity of the M72/AS01 E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study 2016 ·Tuberculosis ·Paul Gillard,Pan‐Chyr Yang,Manfred Danilovitš,Wei‐Juin Su,Shih-Lung Cheng,Lea Pehme,Anne Bollaerts,Erik Jongert,Philippe Moris,Opokua Ofori‐Anyinam,Marie‐Ange Demoitié,Marcela Castro	55
6	Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting 2015 ·Vaccine ·Adam Penn‐Nicholson,Hennie Geldenhuys,Wivine Burny,Robbert van der Most,Cheryl L. Day,Erik Jongert,Philippe Moris,Mark Hatherill,Opokua Ofori‐Anyinam,Willem A. Hanekom,(unknown),Marie‐Ange Demoitié,Angelique Kany Kany Luabeya,(unknown),Michèle Tameris,Didier Lapierre,Thomas J. Scriba	92
7	Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy 2014 ·AIDS ·(unknown),Matthias Cavassini,R Audran,Anne‐Christine Thierry,Anne Bollaerts,Joe Cohen,Marie‐Ange Demoitié,Dawit A. Ejigu,Pascal Mettens,Philippe Moris,Opokua Ofori‐Anyinam,François Spertini	34
8	Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: An open-label randomized controlled trial 2014 ·Tuberculosis ·Olubukola T. Idoko,Olumuyiwa Owolabi,Patrick K. Owiafe,Philippe Moris,Aderonke Odutola,Anne Bollaerts,Ezra Olatunde Ogundare,Erik Jongert,Marie‐Ange Demoitié,Opokua Ofori‐Anyinam,Martin O. C. Ota	42
9	A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive Adults 2013 ·Journal of Clinical Immunology ·Jaime Montoya,Juan Antonio Solon,(unknown),Luz P. Acosta,Anne Bollaerts,Philippe Moris,Michel Janssens,Erik Jongert,Marie‐Ange Demoitié,Pascal Mettens,Salvacion Gatchalian,(unknown),Joe Cohen,Opokua Ofori‐Anyinam	64
10	The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: A randomized controlled phase I/II study 2012 ·Tuberculosis ·François Spertini,R Audran,(unknown),Opokua Ofori‐Anyinam,(unknown),Pierre Vandepapelière,Philippe Moris,Marie‐Ange Demoitié,Pascal Mettens,(unknown),(unknown),Erik Jongert,Joe Cohen,W. Ripley Ballou	42
11	Four year immunogenicity of the RTS,S/AS02A malaria vaccine in Mozambican children during a phase IIb trial 2011 ·Vaccine ·Pedro Aíde,Carlota Dobaño,Jahit Sacarlal,John J. Aponte,Inácio Mandomando,Caterina Guinovart,Quique Bassat,Montse Renom,Laura Puyol,Eusébio Macete,Esperanza Herreros,Amanda Leach,Marie‐Claude Dubois,Marie‐Ange Demoitié,Marc Lievens,Johan Vekemans,Christian Loucq,W. Ripley Ballou,Joe Cohen,Pedro L. Alonso	31
12	Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area 2009 ·PLoS ONE ·Mark E. Polhemus,Shon Remich,Bernhards Ogutu,John Waitumbi,Lucas Otieno,(unknown),James F. Cummings,Kent E. Kester,Christian F. Ockenhouse,Ann Stewart,Opokua Ofori‐Anyinam,(unknown),(unknown),Marc Lievens,Marie‐Claude Dubois,Marie‐Ange Demoitié,Amanda Leach,Joe Cohen,W. Ripley Ballou,D. Gray Heppner	94
13	Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-γ and antibody responses in mice 2008 ·Vaccine ·Joseph P. Shott,Shannon McGrath,Maria Grazia Pau,Jerome Custers,Olga Ophorst,Marie‐Ange Demoitié,Marie‐Claude Dubois,Jack Komisar,(unknown),Kent E. Kester,Patrice Dubois,Joe Cohen,Jaap Goudsmit,D. Gray Heppner,V. Ann Stewart	38
14	Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research 2008 ·Vaccine ·Kent E. Kester,James F. Cummings,Christian F. Ockenhouse,Robin Nielsen,(unknown),Daniel M. Gordon,Robert Schwenk,Urszula Krzych,Carolyn A. Holland,(unknown),Megan Dowler,Jackie Williams,Robert A. Wirtz,Nadia Tornieporth,(unknown),Martine Delchambre,Marie‐Ange Demoitié,W. Ripley Ballou,Joe Cohen,D. Gray Heppner	99
15	Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen 2008 ·Vaccine ·Pascal Mettens,Patrice Dubois,Marie‐Ange Demoitié,(unknown),(unknown),Patricia Bourguignon,V. Ann Stewart,D. Gray Heppner,Nathalie Garçon,Joe Cohen	58
16	Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus 2003 ·The Journal of Immunology ·Vaios Karanikas,Christophe Lurquin,Didier Colau,Nicolas van Baren,Charles De Smet,Bernard Lethé,Thierry Connerotte,Véronique Corbière,Marie‐Ange Demoitié,Danielle Líénard,Brigitte Dréno,Thierry Velu,Thierry Boon,Pierre G. Coulie	88
17	High Frequency of Cytomegalovirus‐Specific Cytotoxic T‐Effector Cells in HLA‐A0201–Positive Subjects during Multiple Viral Coinfections 2000 ·The Journal of Infectious Diseases* ·Xia Jin,Marie‐Ange Demoitié,Sean M. Donahoe,Graham S. Ogg,Sebastian Bonhoeffer,(unknown),Geraldine M. Gillespie,Paul Moss,Wayne B. Dyer,Michael G. Kurilla,Stanley R. Riddell,(unknown),John S. Sullivan,A J McMichael,Cassy Workman,Douglas F. Nixon	58
18	A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals 1999 ·AIDS ·Marie Larsson,Xia Jin,Bharat Ramratnam,Graham S. Ogg,(unknown),Marie‐Ange Demoitié,Andrew J. McMichael,William I. Cox,Ralph M. Steinman,Douglas F. Nixon,Nina Bhardwaj	190
19	Cis-acting elements required for strong stop acceptor template selection during moloney murine leukemia virus reverse transcription 1998 ·Journal of Molecular Biology ·Robert S. Topping,Marie‐Ange Demoitié,(unknown),Alice Telesnitsky	24
20	Peyer's Patches in Murine AIDS: Dissociation Between Lymphoproliferation and Anergy 1997 ·Scandinavian Journal of Immunology ·(unknown),Michel Moutschen,Laurence de Leval,Marie‐Ange Demoitié,Mohamed Trebak,(unknown),Jacques Boniver	3

About Marie‐Ange Demoitié

Marie‐Ange Demoitié is a scholar working on Virology, Infectious Diseases and Immunology, having authored 31 papers that have together received 1.8k indexed citations. Recurring topics across this work include HIV Research and Treatment (14 papers), Tuberculosis Research and Epidemiology (12 papers) and vaccines and immunoinformatics approaches (7 papers). The work is most often cited by research in Virology (611 citations), Immunology (996 citations) and Infectious Diseases (799 citations). Marie‐Ange Demoitié has collaborated with scholars based in Belgium, United States and United Kingdom. Frequent co-authors include Opokua Ofori‐Anyinam, Philippe Moris, Xia Jin, Douglas F. Nixon, Joe Cohen, Pascal Mettens, Graham S. Ogg, Erik Jongert, Andrew J. McMichael and D. Gray Heppner. Their work appears in journals such as Journal of Clinical Investigation, The Journal of Immunology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact